HOLOGIC®
The Science of Sure

The highly evolved senses of a hunter.

With true sample-to-result automation, adaptable workflow options and assays using proven TMA technology, the Panther system was built for maximum efficiency.

PANTHER®

Control your workflow.

The Panther® system provides the flexibility of multiple testing options on **one integrated solution**.

Aptima Combo 2® Assay for CT/NG

- Worldwide leader in CT/NG testing.[1,2]
- Provides increased sensitivity compared to DNA tests.[3]

Aptima® Trichomonas vaginalis Assay

- Only Aptima Trichomonas vaginalis has been shown to detect 100% of TV infection in both symptomatic and asymptomatic patients.[4-8]

Aptima® HPV Assay

- Maximizes the benefits of screening with the same excellent sensitivity as DNA-based assays.[9]
- Minimizes potential harms with fewer false positive results compared to DNA-based testing.[9]

Aptima® HPV 16 18/45 Genotype Assay

- First FDA-approved test for HPV 16, 18 and/or 45.
- Adding as a reflex test may pinpoint the genotypes associated with up to 94% of all cervical adenocarcinoma.[10]

Aptima® Zika Virus Assay*

- Our commitment to public health with exquisite sensitivity in serum, plasma and urine sample types.
- Two target region design for amplification and detection of Zika virus RNA is an obvious benefit if unexpected mutations arise.[11]

Aptima® HIV-1 Quant Assay

- Full automation meets excellent performance in HIV-1 viral load monitoring.
- A dual target approach against highly conserved regions in the HIV genome, pol and LTR; a sophisticated primer design; and redundancy of oligonucleotides for protection against mutations.[12]

Aptima® HCV Quant Dx Assay

- Ultrasensitive, highly precise performance from diagnosis to sustained virologic response.[13]
- High viral load result agreement between Aptima and comparators for confidence in switching assays without disrupting patient care.[14,15]

In Development

- HBV
- HSV 1 & 2
- *Mycoplasma genitalium*
- Bacterial vaginosis
- Candida vaginitis

* The Aptima Zika Virus assay:
- This test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of RNA from Zika virus and diagnosis of Zika virus infection, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection undersection 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Control your productivity.

The only system to offer **true sample-to-result automation** featuring random and continuous access to release you from the confines of batch testing.

Leverage Limited Resources

- Proven lowest hands-on time minimizes labor.[16]
- Consolidated testing maximizes resource efficiency.
- Flexibility to utilize a complete kit means eliminating waste.
- Controls/calibrators only need to be run every 24 hours, reducing cost per reportable.

Increase Lab Productivity and Efficiency

- Random access allows you to load any sample in any order, at any time – no more batch constraints.
- Fully automated platform lets you increase test volumes without increasing labor, helping you do more with less.
- Ability to run multiple assays from one patient sample concurrently decreases turnaround time and minimizes labor.
- Consolidation onto a single platform frees up tech time for additional testing or new services.

> *"The design of this instrument allowed continuous access to reagents and samples, with loading and unloading in any order, while the instrument was processing. These characteristics may enable a more efficient workflow than can be achieved by instruments which are designed for batching."*[16]
>
> *– Ratnam, et al. 2014*

Total Hands-on Time for Each Instrument for 96 and 192 Tests[16]



Put the Panther® system to work in your lab.

Specifications

Sample Throughput.....**TMA assays:** 3.5 hrs to first result; up to 275 samples processed 8 hrs
RT-TMA assays: 2.7 hrs to first result; up to 320 samples processed in 8 hrs; up to 750 samples processed in 15.2 hrs

Sample Capacity.....120 sample tubes on board with continuous access; 8 racks of 15 tubes each

Reagent Capacity.....1 reagent kit per lane; 4 lanes available to load any combination of assays 2,000-test onboard universal fluids capacity

Waste Capacity.....750 tests

Component Dimensions (w x d x h)
Panther System.....48 in (122 cm) x 32 in (81.5 cm) x 69 in (175 cm)
UPS (Optional).....8.4 in (21.4 cm) x 16.1 in (41 cm) x 12.8 in (32.5 cm)

Weight
Panther System.....800 lb (363 kg)
UPS (Optional).....76 lb (34.5 kg)

Sample Tube
Barcode Types.....Code 39, Code 93, Code 128 (ISBT 128), Interleaved 2 of 5, and Codabar

Environmental Requirements
Ambient Temperature.....59°F-86°F (15°C-30°C)
Relative Humidity.....20%-85%

Electrical Requirements
Electrical Input.....100-240 +/- 10% VAC, 50-60 Hz, single phase
Current Input.....Minimum of 15-amp circuit (dedicated); 20-amp circuit (dedicated) if used with optional UPS
Current Draw.....Average: 700 W
Peak: 1400 W
- 100 VAC circuit draws 13 amps
- 240 VAC circuit draws 5.4 amps

System Output
Heat Dissipation.....550 watts (1878 BTU/hour) during steady state
Liquid Waste.....Waste fluids drain to removable containers



Small footprint, highest throughput per square foot.[17]

hologic.com | diagnostic.solutions@hologic.com | 888.484.4747

References: 1. Piper Jaffrey Investment Research, Sixth Annual Molecular Diagnostics Update, June 2011. **2.** Sannes & Associates, Inc. CT and GC Testing Market Report, January 2011. **3.** Chernesky M, et al. *J Clin Microbiol.* 2006;44(2):400-405. **4.** Aptima Trichomonas vaginalis Assay [package insert]. 503684-IFU-PI, Rev. 001. San Diego, CA: Hologic, Inc.; 2016. **5.** Huppert JS, et al. *Clin Infect Dis.* 2007;45(2):194-8. **6.** Andrea, et al. *J Clin Microbiol.* 2011;49(3):866-9. **7.** Nye MB, et al. AJOG. 2009;200(2):188.i1-188.e7. **8.** Wendel KA, et al. *Clin Infect Dis.* 2002;35(5):576-80. **9.** Aptima HPV Assay [package insert]. AW-12820, Rev. 001. San Diego, CA: Hologic, Inc.; 2015. **10.** de Sanjose S, et al. *Lancet Oncol.* 2010;11(11):1048-56. **11.** Aptima Zika Virus Assay [package insert]. AW-15406-REG, Rev. 002. San Diego, CA: Hologic, Inc.; 2016. **12.** Aptima HIV-1 Quant Assay [package insert]. AW-13242-001, Rev. 002. San Diego, CA: Hologic, Inc.; 2017. **13.** Aptima HCV Quant Dx Assay [package insert] #AW-14498, Rev.004, San Diego, CA; Hologic, Inc., 2017. **14.** Worlock A, et al. Poster presented at: 19th Annual Meeting of the European Society for Clinical Virology (ESCV); September 14-17, 2016; Lisbon, Portugal. **15.** Clark C, et al. Poster presented at: 13th European HIV and Hepatitis Meeting; June 3-5, 2015; Barcelona, Spain. **16.** Ratnam S, et al. *J Clin Microbiol.* 2014;52(7); 2299-2304. **17.** Data on File. Hologic, Inc.; 2017.